New Strategies in Academic-Industry Collaborations

Published by: Decision Resources

Published: Jun. 11, 2009 - 26 Pages

Table of Contents

Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction to Academic-Industry Collaborations

Impact of Bayh-Dole on Technology Transfer to Industry

Bayh-Dole and the Rise of Technology Transfer Offices

Academia: A Rich Source of Novel Inventions and Innovation for Drug Discovery

Challenges in Academic-Industry Relationships

New Approaches in Academic-Industry Collaborations

Collaborative Models

Translational Medicine

Academic and Industry Centers for Drug Discovery

Academic Drug Discovery Centers

Pharmaceutical R&D Centers

Pharmaceutical R&D Incubators

Academic-Industry Collaborations of Note

Merck/Harvard Medical School

GSK/Harvard Stem Cell Institute

GSK/Immune Disease Institute

AstraZeneca/Columbia University Medical Center

Pfizer/ Washington University

Pfizer/University of California, San Francisco

Janssen Pharmaceutica/Vanderbilt University

Centocor/University of Michigan

Novartis/MIT

Outlook for Academic-Industry Collaborations

Tables

1. Select Academic Drug Discovery Centers

2. Select Pharmaceutical R&D Centers

3. Select Academic-Industry Collaborations

4. R&D Expenditures of Top Pharmaceutical Companies, 2008

Figures

1. Annual National Institutes of Health Budget, 2001-2010

2. Staffing of U.S. Technology Transfer Offices, 1998-2007

3. Relationships Among Academic Research Institutions and External Entities

4. Industrial Research Support for U.S. Universities, Hospitals, and Research Institutions

5. Top 20 Academic Biotechnology Patent Filers, 2002-2006

Abstract

• Pharmaceutical companies have recently formed numerous collaborations with large research institutions. What factors are driving this interest? What are the key features of recent collaborative agreements? How does each organization benefit from these arrangements?
• The environment of academic technology transfer to industry is changing. What impact has the Bayh-Dole Act had on technology transfer? How do academic institutions manage academicindustry relationships? Which institutions are leading in innovation and commercialization of technology?
• Drug developers are experimenting with different approaches to academic-industry relations. Which key collaborations illustrate these new approaches? What strategic interests of the pharmaceutical industry do these agreements serve? How will universities and companies measure success?
• Relationships between academia and industry present special challenges. How do the missions and goals of academia and industry differ? What confl icts can arise with respect to industry funding of academic researchers? How can institutions and companies manage these differences?

• Factors in academic-industry collaborations: historical relationships, dwindling pharmaceutical pipelines, diminishing federal funding for academia.
• Technology transfer: impact of Bayh-Dole, tech transfer offices, inventions and innovation, challenges in academic-industry relationships.
• New approaches in academic-industry relationships: close-collaboration, broad-scope, early-stage research.
• Translational medicine: theme of collaborations, goals, motivations.
• Drug discovery centers: academic centers for dug discovery, industry discovery centers, pharmaceutical incubators.
• Notable collaborators: AstraZeneca, Centocor, GlaxoSmithKline, Janssen Pharmaceutica, Merck, Novartis, Pfizer; Columbia University Medical Center, Harvard Medical School, Harvard Stem Cell Institute, Immune Disease Institute, MIT, University of California, San Francisco, University of Michigan, Vanderbilt University, Washington University.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.